Vanguard Group Inc. Trims Stake in MaxCyte, Inc. (NASDAQ:MXCT)

Vanguard Group Inc. cut its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 6.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,429,681 shares of the company’s stock after selling 345,587 shares during the quarter. Vanguard Group Inc. owned 0.05% of MaxCyte worth $22,587,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. River Global Investors LLP boosted its stake in shares of MaxCyte by 57.7% in the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock valued at $13,494,000 after buying an additional 1,190,630 shares during the period. Royce & Associates LP increased its holdings in shares of MaxCyte by 146.9% in the fourth quarter. Royce & Associates LP now owns 799,873 shares of the company’s stock valued at $3,327,000 after purchasing an additional 475,949 shares during the period. Rice Hall James & Associates LLC acquired a new stake in MaxCyte in the fourth quarter valued at about $1,098,000. Gagnon Securities LLC grew its stake in shares of MaxCyte by 234.1% during the 4th quarter. Gagnon Securities LLC now owns 197,326 shares of the company’s stock worth $821,000 after purchasing an additional 138,257 shares during the period. Finally, Barclays PLC raised its holdings in MaxCyte by 329.3% during the third quarter. Barclays PLC now owns 165,765 shares of the company’s stock worth $645,000 after purchasing an additional 127,156 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MXCT has been the topic of several analyst reports. Stifel Nicolaus decreased their price objective on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. BTIG Research set a $6.00 price target on MaxCyte and gave the stock a “buy” rating in a research note on Wednesday, March 12th.

MaxCyte Stock Performance

MXCT opened at $2.65 on Wednesday. The company has a market capitalization of $281.73 million, a P/E ratio of -7.79 and a beta of 1.39. MaxCyte, Inc. has a 1-year low of $2.21 and a 1-year high of $5.26. The company has a 50-day moving average of $3.26 and a 200-day moving average of $3.75.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.